Free Trial

Senseonics Q1 2024 Earnings Report

Senseonics logo
$0.46 +0.02 (+4.03%)
(As of 12/20/2024 05:45 PM ET)

Senseonics EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.03
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Senseonics Revenue Results

Actual Revenue
$5.05 million
Expected Revenue
$4.76 million
Beat/Miss
Beat by +$290.00 thousand
YoY Revenue Growth
N/A

Senseonics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Senseonics Earnings Headlines

Senseonics provides update on Eversense 365 launch
Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Senseonics Holdings Expands with Innovative Diabetes Solutions
Senseonics Holdings Reports Q3 2024 Earnings Results
See More Senseonics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senseonics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senseonics and other key companies, straight to your email.

About Senseonics

Senseonics (NYSE:SENS), a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

View Senseonics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings